{"public_id":"co_e4cafdf0d433cf8f9b7e9e273cb61a4f","status":"active","merged_into_public_id":null,"resolved_public_id":"co_e4cafdf0d433cf8f9b7e9e273cb61a4f","name":"AMN107","description":"An improved potency, selective Abl inhibitor being evaluated in clinical trials for imatinib-resistant CML.","aliases":[],"types":["drug","inhibitor"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":554884,"title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","citation_count":1093,"url":"https://sah.borca.ai/papers/554884"}],"claims":[{"public_id":"cl_77338944702374b0bba5f42e8675e2f8","text":"AMN107 and BMS-354825 are being evaluated in clinical trials for treating imatinib-refractory CML.","corpus_id":554884,"url":"https://sah.borca.ai/claims/cl_77338944702374b0bba5f42e8675e2f8"},{"public_id":"cl_8aa446d249c137bc48b1d644323aee80","text":"AMN107 and BMS-354825 maintain similar improvements in potency for all imatinib-resistant mutants tested except T315I.","corpus_id":554884,"url":"https://sah.borca.ai/claims/cl_8aa446d249c137bc48b1d644323aee80"},{"public_id":"cl_99e15348defea28da9c0733b93af1323","text":"AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl.","corpus_id":554884,"url":"https://sah.borca.ai/claims/cl_99e15348defea28da9c0733b93af1323"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_e4cafdf0d433cf8f9b7e9e273cb61a4f","url":"https://sah.borca.ai/concepts/co_e4cafdf0d433cf8f9b7e9e273cb61a4f"}